Figure 1: Percentage of Cancer Deaths, by Type: 2007-2020
Figure 2: Global Tumor Genomics Market Value, 2018-2028
Figure 3: Drivers and Restraints of Global Tumor Genomics Market
Figure 4: Share of Key Developments and Strategies, January 2017-February 2020
Figure 5: Global Tumor Genomics Market (by Product), 2018-2028
Figure 6: Global Tumor Genomics Market (by Technique), 2018-2028
Figure 7: Global Tumor Genomics Market (by Application), 2018-2028
Figure 8: Global Tumor Genomics Market (by End User), 2018-2028
Figure 9: Global Tumor Genomics Market (by Cancer Type), 2018-2028
Figure 10: Global Tumor Genomics Market (by Region): 2019 and 2028
Figure 3.1: Global Tumor Genomics Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Top-Down Approach (Segment-Wise Analysis)
Figure 3.6: Bottom-up Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 3.8: Assumptions and Limitations
Figure 3.9: Segmentation of the Global Tumor Genomics Market
Figure 4.1: Evolution of Tumor Genomic Techniques
Figure 4.2: Global Tumor Genomics Market Size, 2018-2028
Figure 5.1: Incidence of Different Cancers (2014-2017)
Figure 7.1: Competitive Landscape, January 2017-February 2020
Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020
Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020
Figure 7.4: New Product Launches (by Company), January 2017-February 2020
Figure 7.5: Others (by Company), January 2017-February 2020
Figure 7.6: Market Share Analysis for the Global Tumor Genomics Market, by Company (2019)
Figure 7.7: Growth Share Matrix: Global Tumor Genomics Market (by Company), 2018-2019
Figure 8.1: Global Tumor Genomics Market (by Product)
Figure 8.2: Global Tumor Genomics Market (by Product), 2018-2028
Figure 8.3: Global Tumor Genomics Market for Assays and Kits, 2018-2028
Figure 8.4: Global Tumor Genomics Market for Instruments, 2018-2028
Figure 9.1: Global Tumor Genomics Market, by Techniques
Figure 9.2: Global Tumor Genomics Market (by Technique), 2018-2028
Figure 9.3: Global Tumor Genomics Market (Technique: Next-Generation Sequencing), 2018-2028
Figure 9.4: Global Tumor Genomics Market (Technique: Polymerase Chain Reaction), 2018-2028
Figure 9.5: Global Tumor Genomics Market (Technique: Microarray) , 2018-2028
Figure 9.6: Global Tumor Genomics Market (Technique: In-Situ Hybridization), 2018-2028
Figure 9.7: Global Tumor Genomics Market (Technique: Immunohistochemistry), 2018-2028
Figure 9.8: Global Tumor Genomics Market (Technique: Other Technologies {Mass Spectrometry and Flow Cytometry}), 2018-2028
Figure 10.1: Global Tumor Genomics Market, by Application
Figure 10.2: Global Tumor Genomics Market (by Application), 2018-2028
Figure 10.3: Global Tumor Genomics Market (Application: Diagnostics and Monitoring), 2018-2028
Figure 10.4: Global Tumor Genomics Market (Application: Drug Discovery and Development), 2018-2028
Figure 10.5: Global Tumor Genomics Market (Application: Biomarker Discovery), 2018-2028
Figure 11.1: Global Tumor Genomics Market, by End User
Figure 11.2: Global Tumor Genomics Market (by End User), 2018-2028
Figure 11.3: Global Tumor Genomics Market (End User: Academics and Research Organizations), 2018-2028
Figure 11.4: Global Tumor Genomics Market (End User: Hospitals and Ambulatory Clinics), 2018-2028
Figure 11.5: Global Tumor Genomics Market (End User: Clinical and Diagnostic Laboratories), 2018-2028
Figure 11.6: Global Tumor Genomics Market (End User: Biotechnology and Pharmaceutical Company), 2018-2028
Figure 12.1: Global Tumor Genomics Market, by Cancer Type
Figure 12.2: Global Tumor Genomics Market (by Cancer Type), 2018-2028
Figure 12.3: Global Tumor Genomics Market (Cancer Type: Leukemia), 2018-2028
Figure 12.4: Global Tumor Genomics Market (Cancer Type: Breast Cancer), 2018-2028
Figure 12.5: Global Tumor Genomics Market (Cancer Type: Melanoma), 2018-2028
Figure 12.6: Global Tumor Genomics Market (Cancer Type: Colon Cancer), 2018-2028
Figure 12.7: Global Tumor Genomics Market (Cancer Type: Lung Cancer), 2018-2028
Figure 12.8: Global Tumor Genomics Market (Cancer Type: Prostate Cancer), 2018-2028
Figure 12.9: Global Tumor Genomics Market (Cancer Type: Head and Neck Cancer), 2018-2028
Figure 12.10: Global Tumor Genomics Market (Cancer Type: Others {Ovarian, Pancreatic, and Testicular}), 2018-2028
Figure 13.1: Global Tumor Genomics Market (by Region), 2019 and 2028
Figure 13.2: North America Tumor Genomics Market, 2018-2028
Figure 13.3: North America: Market Dynamics
Figure 13.4: North America Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.5: U.S. Tumor Genomics Market, 2018-2028
Figure 13.6: Canada: Tumor Genomics Market, 2018-2028
Figure 13.7: Europe: Tumor Genomics Market, 2018-2028
Figure 13.8: Europe: Market Dynamics
Figure 13.9: Europe Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.10: Germany Tumor Genomics Market, 2018-2028
Figure 13.11: U.K. Tumor Genomics Market, 2018-2028
Figure 13.12: France Tumor Genomics Market, 2018-2028
Figure 13.13: Italy Tumor Genomics Market, 2018-2028
Figure 13.14: Spain Tumor Genomics Market, 2018-2028
Figure 13.15: Netherlands Tumor Genomics Market, 2018-2028
Figure 13.16: Rest-of-Europe Tumor Genomics Market, 2018-2028
Figure 13.17: Asia-Pacific: Tumor Genomics Market, 2018-2028
Figure 13.18: Asia-Pacific: Market Dynamics
Figure 13.19: Asia-PacificTumor Genomics Market (by Country), 2019 and 2028
Figure 13.20: China Tumor Genomics Market, 2018-2028
Figure 13.21: Japan Tumor Genomics Market, 2018-2028
Figure 13.22: Australia Tumor Genomics Market, 2018-2028
Figure 13.23: India Tumor Genomics Market, 2018-2028
Figure 13.24: Rest-of-Asia-Pacific Tumor Genomics Market, 2018-2028
Figure 13.25: Rest-of-the-World Tumor Genomics Market, 2018-2028
Figure 13.26: Rest-of-the-World (RoW): Market Dynamics
Figure 13.27: Rest-of-the-World Tumor Genomics Market (by Country), 2019 and 2028
Figure 13.28: Latin America Tumor Genomics Market, 2018-2028
Figure 13.29: Middle East & Africa Tumor Genomics Market, 2018-2028
Figure 14.1: Abbott Laboratories: Product Offerings for the Global Tumor Genomics Market
Figure 14.2: Abbott Laboratories: Overall Financials, 2017-2019
Figure 14.3: Abbott Laboratories: Revenue (by Product/Service), 2017-2019
Figure 14.4: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 14.5: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 14.6: Abbott Laboratories: SWOT Analysis
Figure 14.7: Agilent Technologies, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 14.9: Agilent Technologies, Inc.: Revenue (by Business Model), 2017-2019
Figure 14.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 14.11: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 14.12: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.13: Bio-Rad Laboratories, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 14.15: Bio-Rad Laboratories, Inc.: Revenue (by Product/Service), 2016-2018
Figure 14.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
Figure 14.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 14.18: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.19: Danaher Corporation Product Offerings for the Global Tumor Genomics Market
Figure 14.20: Danaher Corporation: Overall Financials, 2017-2019
Figure 14.21: Danaher Corporation: Revenue (by Product/Service), 2017-2019
Figure 14.22: Danaher Corporation: Revenue (by Region), 2017-2019
Figure 14.23: Danaher Corporation: R&D Expenditure, 2017-2019
Figure 14.24: Danaher Corporation: SWOT Analysis
Figure 14.25: F. Hoffman-La-Roche Ltd: Product Offerings for the Global Tumor Genomics Market
Figure 14.26: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 14.27: F. Hoffmann-La Roche Ltd: Revenue (by Product/Service), 2017-2019
Figure 14.28: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 14.29: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2018
Figure 14.30: F. Hoffmann-La Roche AG: SWOT Analysis
Figure 14.31: Fluidigm Corporation: Overall Product Portfolio
Figure 14.32: Fluidigm Corporation: Overall Financials, 2017-2019
Figure 14.33: Fluidigm Corporation: Revenue (by Business Segment), 2016-2018
Figure 14.34: Fluidigm Corporation: Revenue (by Region), 2016-2018
Figure 14.35: Fluidigm Corporation: R&D Expenditure, 2016-2018
Figure 14.36: Fluidigm Corporation: SWOT Analysis
Figure 14.37: General Electric Company: Product Offerings for the Global Tumor Genomics Market
Figure 14.38: General Electric Company: Overall Financials, 2017-2019
Figure 14.39: General Electric Company: Revenue (by Business Model), 2017-2019
Figure 14.40: General Electric Company: Revenue (by Region), 2017-2019
Figure 14.41: General Electric Company: R&D Expenditure, 2017-2019
Figure 14.42: General Electric Company: SWOT Analysis
Figure 14.43: Illumina, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.44: Illumina, Inc.: Overall Financials, 2016-2018
Figure 14.45: Illumina Inc.: Revenue (by Segment), 2016-2018
Figure 14.46: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 14.47: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 14.48: Illumina, Inc.: SWOT Analysis
Figure 14.49: Merck KGaA: Product Offerings for the Global Tumor Genomics Market
Figure 14.50: Merck KGaA: Overall Financials, 2017-2019
Figure 14.51: Merck KGaA: Revenue (by Product/Service), 2017-2019
Figure 14.52: Merck KGaA: Revenue (by Region), 2017-2019
Figure 14.53: Merck KGaA: R&D Expenditure, 2017-2019
Figure 14.54: Merck KGaA: SWOT Analysis
Figure 14.55: Myriad Genetics, Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.56: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 14.57: Myriad Genetics, Inc.: Revenue (by Product/Service), 2017-2019
Figure 14.58: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 14.59: Myriad Genetics, Inc.: SWOT Analysis
Figure 14.60: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 14.61: Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018
Figure 14.62: Pacific Biosciences of California, Inc.: Revenue (by Product/Service), 2016-2018
Figure 14.63: Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018
Figure 14.64: Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018
Figure 14.65: Pacific Biosciences: SWOT Analysis
Figure 14.66: PerkinElmer: Product Offerings for the Global Tumor Genomics Market
Figure 14.67: Perkin Elmer: Overall Financials, 2017-2019
Figure 14.68: PerkinElmer: Revenue (by Products & Services), 2017-2019
Figure 14.69: PerkinElmer: Revenue (by Region), 2017-2019
Figure 14.70: PerkinElmer: R&D Expenditure, 2017-2019
Figure 14.71: PerkinElmer lnc.: SWOT Analysis
Figure 14.72: QIAGEN: Product Offerings for the Global Tumor Genomics Market
Figure 14.73: QIAGEN: Overall Financials, 2016-2018
Figure 14.74: QIAGEN: Revenue (by Business Model), 2016-2018
Figure 14.75: QIAGEN: Revenue (by Region), 2016-2018
Figure 14.76: QIAGEN: R&D Expenditure, 2016-2018
Figure 14.77: QIAGEN: SWOT Analysis
Figure 14.78: Siemens Healthineers AG: Product Offerings for the Global Tumor Genomics Market
Figure 14.79: Siemens Healthineers AG Overall Financials, 2017-2019
Figure 14.80: Siemens Healthineers AG: Revenue (by Product and Services), 2017-2019
Figure 14.81: Siemens Healthineers AG: Revenue (by Region), 2017-2019
Figure 14.82: Siemens Healthineers AG: R&D Expenditure, 2017-2019
Figure 14.83: Siemens Healthineers AG: SWOT Analysis
Figure 14.84: Thermo Fisher Scientific Inc.: Product Offerings for the Global Tumor Genomics Market
Figure 14.85: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 14.86: Thermo Fisher Scientific Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 14.87: Thermo Fisher Scientific Inc.: Net Revenue (by Region), 2017-2019
Figure 14.88: Thermo Fisher Scientific Inc.: R&D Expense, 2017-2019
Figure 14.89: Thermo Fisher Scientific, Inc.: SWOT Analysis